دورية أكاديمية
أعرض في EDS

Addition of contrast in ultrasound screening for hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان: Addition of contrast in ultrasound screening for hepatocellular carcinoma.
المؤلفون: McGillen K; Penn State Health Milton S Hershey Medical Center, Department of Radiology, 500 University Drive, Hershey, PA 17033, USA., Aljabban N; Penn State Health Milton S Hershey Medical Center, Department of Medicine, 500 University Drive, Hershey, PA 17033, USA., Wu R; Rutgers Robert Wood Johnson Medical School, Department of Radiology, MEB #404, 1 Robert Wood Johnson Place, New Brunswick, NJ 08901, USA., Shin B; George Washington University Hospital, Department of Radiology, 900 23rd St NW 2nd Floor, Washington DC 20037, USA., Schreibman I; Penn State Health Milton S Hershey Medical Center, Department of Medicine, 500 University Drive, Hershey, PA 17033, USA., Luke F; Penn State Health Milton S Hershey Medical Center, Department of Radiology, 500 University Drive, Hershey, PA 17033, USA., Birkholz J; Penn State Health Milton S Hershey Medical Center, Department of Radiology, 500 University Drive, Hershey, PA 17033, USA.
المصدر: Research in diagnostic and interventional imaging [Res Diagn Interv Imaging] 2024 Feb 07; Vol. 9, pp. 100039. Date of Electronic Publication: 2024 Feb 07 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Masson SAS Country of Publication: France NLM ID: 9918574385706676 Publication Model: eCollection Cited Medium: Internet ISSN: 2772-6525 (Electronic) Linking ISSN: 27726525 NLM ISO Abbreviation: Res Diagn Interv Imaging Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Paris] : Elsevier Masson SAS, [2022]-
مستخلص: Objective: Screening ultrasound for hepatocellular carcinoma (HCC) identifies lesions which require further characterization by a contrast-enhanced exam to non-invasively diagnose HCC. While ultrasound is recommended in screening, some HCC can be occult on grayscale imaging. The purpose of this study was to determine if the addition of ultrasound contrast (sulfahexafluoride) to screening ultrasound for HCC can identify more HCC lesions than grayscale sonographic imaging alone.
Methods: All HCC screening ultrasounds that also had contrast were evaluated in this retrospective study. Patients with a focal lesion seen only after administration of contrast (OAC) were noted, as well as any follow-up imaging or pathology results. Additional variables collected included patient demographics, cirrhosis type, and laboratory values.
Results: 230 unique patients were included, of which 160 had imaging or pathology follow-up. 18 of these patients had an OAC lesion, of which 17 had follow-up. Among these OACs, there was one LIRADS M lesion (1/18, 5.6 %) and one bland portal vein thrombus identified, which were both confirmed on follow-up imaging. All LIRADS 4 OAC lesions were downgraded. No additional HCC were identified on follow-up imaging or pathology of these patients.
Conclusion: Addition of contrast to screening ultrasound did identify additional lesions, portal vein thrombus, and high grade malignancy. However, as the incidence of OAC lesions was low (7.8 %, 18/230) and most of the lesions were not malignant, addition of post contrast sweeps through the liver is of low value in the low to medium at-risk cirrhotic population in identifying occult HCC.
Competing Interests: The other co-authors have no competing interests to declare.
(© 2023 The Author(s).)
References: Radiol Med. 2008 Oct;113(7):978-91. (PMID: 18779929)
J Hepatol. 2022 Jul;77(1):128-139. (PMID: 35139400)
AJR Am J Roentgenol. 2021 Mar;216(3):579-580. (PMID: 32812769)
Diagn Interv Imaging. 2023 Jan;104(1):24-36. (PMID: 36272931)
Clin Hemorheol Microcirc. 2020;74(3):327-339. (PMID: 31658052)
Abdom Radiol (NY). 2018 Jan;43(1):127-142. (PMID: 28819825)
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. (PMID: 31439937)
Radiology. 2020 Feb;294(2):329-339. (PMID: 31793849)
Liver Cancer. 2019 Jul;8(4):271-280. (PMID: 31602370)
AJR Am J Roentgenol. 2018 Apr;210(4):715-719. (PMID: 29412016)
Abdom Radiol (NY). 2021 Sep;46(9):4170-4177. (PMID: 33956204)
Clin Mol Hepatol. 2013 Mar;19(1):1-16. (PMID: 23593604)
Hepatology. 2018 Aug;68(2):723-750. (PMID: 29624699)
Ultraschall Med. 2011 Dec;32(6):593-7. (PMID: 22161556)
Yonsei Med J. 2006 Feb 28;47(1):105-12. (PMID: 16502491)
Radiology. 2019 Sep;292(3):638-646. (PMID: 31287387)
Clin Gastroenterol Hepatol. 2011 Feb;9(2):161-7. (PMID: 20920597)
N Engl J Med. 2019 Apr 11;380(15):1450-1462. (PMID: 30970190)
Ultraschall Med. 2010 Oct;31(5):492-9. (PMID: 20652854)
Medicines (Basel). 2020 Aug 27;7(9):. (PMID: 32867068)
فهرسة مساهمة: Keywords: Contrast-enhanced ultrasound; Hepatocellular carcinoma; Screening, Cirrhosis; Ultrasound
تواريخ الأحداث: Date Created: 20240730 Latest Revision: 20240731
رمز التحديث: 20240731
مُعرف محوري في PubMed: PMC11265193
DOI: 10.1016/j.redii.2023.100039
PMID: 39076583
قاعدة البيانات: MEDLINE
الوصف
تدمد:2772-6525
DOI:10.1016/j.redii.2023.100039